Avid Logo June 2022.jpg
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
30 nov. 2023 16h05 HE | Avid Bioservices, Inc
TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target
30 nov. 2023 08h00 HE | Shape Therapeutics, Inc.
ShapeTX announces the expansion of its drug discovery partnership with Roche with new target
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
28 nov. 2023 16h05 HE | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Global Gene Therapy Market
Global Gene Therapy Research Report 2023-2028: Increasing Regulatory Approvals, Growing Investments, Rising Demand for Cell & Gene Therapies
17 nov. 2023 09h13 HE | Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area...
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
17 nov. 2023 08h00 HE | Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Global Precision Medicine Market
Precision Medicine Market Global Forecast to 2028: Increasing Regulatory Approvals for Personalized Therapeutics
17 nov. 2023 01h43 HE | Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare...
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
16 nov. 2023 06h00 HE | Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...
AMR Logo.png
Regenerative Medicine Market Is Projected to Reach an Estimate of $83,196.72 Million by 2030: Allied Market Research
14 nov. 2023 10h51 HE | Allied Market Research
Wilmington, Delaware, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Allied Market Research recently published a report, titled, “Regenerative Medicine Market by Product Type (Gene Therapy, Cell Therapy, Tissue...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
10 nov. 2023 07h30 HE | Ocugen
MALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
09 nov. 2023 16h05 HE | Adverum Biotechnologies, Inc.
- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels...